Antonio Ocejo, MD, discusses supportive care implications from new data comparing ipilimumab/nivolumab in older vs younger age groups with mccRCC.
Antonio Ocejo, MD
Advertisement
Antonio Ocejo, MD, is a fellow at Memorial Sloan Kettering Cancer Center in New York, New York.
Articles by Antonio Ocejo, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Oncology Nursing News
1
National Cancer Institute Explores Ivermectin as a Potential Cancer Therapy
2
Dr. Nicholas Hornstein on ctDNA, Colorectal Cancer and Why Better Drugs Are Coming
3
FDA Approves Sacituzumab Govitecan-hziy for First-Line Triple-Negative Breast Cancer
4
GLP-1 Therapies May Reduce Cardiovascular Risks for Breast Cancer Survivors
5